Browse grants
Federal and state grant opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying. Or browse the complete index →
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R33) opportunity funds early-stage translational work to optimize medical device prototypes, develop diagnostic assays, and create research tools for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Due Dec 23, 2027National Institutes of Health · Up to $350K
This NHLBI Catalyze (R33) opportunity funds rigorous validation of transformative, multi-use platforms or technologies that can advance detection, diagnosis, treatment, or prevention of heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $350,000.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R61/R33) phased opportunity funds target identification and validation plus preliminary product or lead-series identification for small molecules, biologics, and combination products treating heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R33) opportunity funds early-stage translational work to identify and characterize therapeutic candidates and combination products (small molecules and biologics) for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityNPS Cooperative Ecosystems Studies Units (CESU) Master Cooperative Agreements
Due Dec 31, 2027National Park Service · Amount varies
This National Park Service opportunity offers Master Cooperative Agreements to participants in the Cooperative Ecosystem Studies Units (CESU) network across listed regions, supporting research, technical assistance, education, and capacity building. Only existing CESU network partners may apply, so applicants must already have joined the network. No specific award amount is provided.
ResearchersSchools & universitiesGovernment / tribalNarrow eligibilityDEVCOM ANALYSIS CENTER BROAD AGENCY ANNOUNCEMENT FOR APPLIED RESEARCH
Due Jan 4, 2028Dept of the Army -- Materiel Command · Amount varies
This U.S. Army DEVCOM Analysis Center Broad Agency Announcement solicits applied-research proposals supporting Army modernization, tool development, and data curation. Eligibility is broad, including universities, nonprofits, state and local governments, foreign organizations, and for-profit firms (large and small businesses). It uses a whitepaper-then-proposal process; no specific award amount is stated.
ResearchersNonprofitsSmall businessSchools & universities+2 moreNIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of drug, biologic, device, or procedure intervention clinical trials within NIDCR's mission. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityStimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIH SHINE (R01) opportunity supports innovative basic and early translational research in nonmalignant hematology, relevant to NIDDK, NIA, and NHLBI missions. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityContinuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Amount varies
This NIDCR (UH3) opportunity funds competing renewal or competitive revision of ongoing clinical trials already supported by NIDCR; a clinical trial is required. Because it continues existing NIDCR-funded trials, it is effectively limited to current grantees and not open to new projects. It is aimed at research and academic institutions; foreign organizations are not eligible. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityNIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Due Jan 6, 2028National Institutes of Health · Up to $500K
This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of behavioral and social intervention clinical trials for dental, oral, or craniofacial conditions, with a milestone-driven planning phase before transition to a full trial. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibilityNIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $50K
The NIH parent Small Research Grant (R03, clinical trial not allowed) supports small, short-term projects such as pilot and feasibility studies, secondary data analysis, and methodology development. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. The award is capped at about $50,000. The small budget suits research institutions pursuing limited-scope projects to generate preliminary data.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreDevelopment of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $200K
This NIH ORIP (R21) opportunity funds research to develop, improve, and preserve animal models and related biological materials with broad applicability across multiple NIH institutes; single-disease or single-institute projects are out of scope. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $200,000.
ResearchersSchools & universitiesNarrow eligibilityDevelopment of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIH (R61/R33) opportunity funds discovery and early evaluation of candidate biomarkers for neurological and neuromuscular disorders, requiring preliminary human-sample evaluation. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityThe Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)
Due Jan 7, 2028National Institutes of Health · Amount varies
An NIH research project grant (R01, clinical trials optional) supporting population-based research on how work and occupation influence health outcomes among populations with health disparities. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations, foreign components of U.S. organizations, and foreign components are not eligible. No specific award amount is stated. This suits research institutions conducting population health-disparities research.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreScreening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Amount varies
An NIH research project grant (R01, clinical trial not allowed) supporting screening and functional validation of genomic variants linked to human congenital anomalies, developmental disabilities, and inborn errors of metabolism. A broad set of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a basic-science genomics mechanism for research institutions.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreMechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Due Jan 7, 2028National Institutes of Health · Up to $500K
This NCI (R01) opportunity funds investigator-initiated studies on the mechanisms by which bariatric surgery affects cancer risk. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibilityMechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Amount varies
An NIH/NCI exploratory grant (R21, clinical trial not allowed) funding proof-of-concept studies on the mechanisms by which bariatric surgery affects cancer risk. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. Projects must address feasibility not already established in the literature, so this suits research institutions with relevant preliminary direction.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreNIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
Due Jan 7, 2028National Institutes of Health · Amount varies
The NIH parent Exploratory/Developmental Research Grant (R21, clinical trial required) supports early-stage research projects with at least one clinical trial, aligned with participating NIH institutes' missions. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. The clinical-trial requirement makes this best suited to research institutions with trial capacity.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreFocused Technology Research and Development (R01 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Amount varies
This NIH award funds research projects developing new technologies to advance biomedical knowledge acquisition, aimed at institutions including HBCUs, Hispanic-serving institutions, and tribal colleges, among others. Foreign organizations and their non-U.S. components are not eligible to apply. No specific dollar amount is listed, and the deadline is not imminent.
Schools & universitiesResearchersNarrow eligibilityMolecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Due Jan 7, 2028National Institutes of Health · Up to $500K
This NIH (R01) opportunity funds development and use of molecular imaging methods to study inflammation in cancer in vivo, encouraging collaboration between cancer biologists and imaging scientists. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.
ResearchersSchools & universitiesLarge awardNarrow eligibility